A Clinical Study on the Safety and Effectiveness of Donor Derived CD19 CAR-T Cells in the Treatment of R/R B-cell Acute Lymphoblastic Leukemia
Latest Information Update: 03 Feb 2025
Price :
$35 *
At a glance
- Drugs Anti-CD19 chimeric-antigen-receptor-T-cell-therapy-Yake-Biotechnology (Primary)
- Indications B-cell lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Adverse reactions
- 03 Feb 2025 New trial record